{
  "id": 19395064,
  "title": "Taking Ozempic or Wegovy? The FDA says there’s a new warning you shouldn’t ignore",
  "url": "https://urgent.news/2026/11/10/taking-ozempic-or-wegovy-the-fda-says-theres-a-new-warning-you",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-10T20:33:51.000Z",
  "source": {
    "name": "Fast Company",
    "slug": "fast-company",
    "url": "https://www.fastcompany.com/91639517/taking-ozempic-or-wegovy-the-fda-says-theres-a-new-warning-you-shouldnt-ignore"
  },
  "original_language": "en",
  "account": "The FDA has issued a new warning label for GLP-1 drugs, including popular medications like Ozempic and Wegovy, due to a rare but serious side effect. These drugs, which are used to treat diabetes, obesity, and other conditions, may increase the risk of a condition called nonarteritic anterior ischemic optic neuropathy (NAION). NAION can cause sudden, painless vision loss in one eye and potentially lead to permanent vision loss. While the exact cause of NAION is not known, it occurs when blood flow to the front of the optic nerve is reduced. The FDA notes that cases of NAION have been reported for all currently marketed GLP-1 drugs. The warning will be included in the \"warnings and precautions\" section of the drugs' prescription labels. GLP-1 drugs have been hailed as a medical breakthrough for treating various health issues, but researchers continue to discover more about their effects and mechanisms. The FDA began investigating the connection between GLP-1 drugs and vision loss after a 2024 study linked semaglutide use in diabetes patients to an increased risk of NAION. However, the observational nature of the study means it cannot definitively prove a causal link between the drugs and vision loss. Other risk factors for NAION include smoking, diabetes, high blood pressure, sleep apnea, anemia, and kidney disease. The European Medicines Agency has also found that semaglutide use in adults with type 2 diabetes is associated with a roughly two-fold increase in NAION risk compared to non-users. The FDA believes the risk of vision loss is very low but statistically significant enough to warrant reporting. If individuals experience sudden vision changes in one eye, they should immediately inform their healthcare provider.",
  "summary": "The FDA is adding a new warning label onto GLP-1 drugs like Ozempic and Zepbound for a rare side effect with serious risk. All GLP-1 drug makers will now be required to include new safety warnings informing patients that the medications could increase risk of sudden vision loss from a condition known as nonarteritic anterior ischemic optic neuropathy (NAION). The condition, which is not common,…",
  "key_points": [
    "FDA issues new warning label for GLP-1 drugs like Ozempic and Wegovy.",
    "These drugs may increase risk of nonarteritic anterior ischemic optic neuropathy (NAION).",
    "NAION can cause sudden, painless vision loss in one eye."
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}